9.13 Metabolic Alterations in Patients with Primary Aldosteronism (PA): Role of Adipokines
- PDF / 45,854 Bytes
- 1 Pages / 592.441 x 751.181 pts Page_size
- 95 Downloads / 191 Views
High Blood Press Cardiovasc Prev 2008; 15 (3): 171-215 1120-9879/08/0003-0171/$48.00/0 © 2008 Adis Data Information BV. All rights reserved.
Metabolic Aspects and Mechanisms 9.13 Metabolic Alterations in Patients with Primary Aldosteronism (PA): Role of Adipokines L. Petramala (1), G. Iacobellis (2), D. Cotesta (1), L. Zinnamosca (1), E. D’Erasmo (1), C. Letizia (1) ` degli (1)Day Hospital di Medicina Interna e dell’Ipertensione Arteriosa Universita Studi “Sapienza”, Roma, Italy; (2)Department of Medicine McMaster University, Hamilton, Canada Aim. To evaluate the prevalence of metabolic syndrome (MS), according to ATP/NCEP 2001 criteria in patients with PA comparing to the prevalence of MS in patients with essential hypertension (EH), moreover the circulating levels of adipokines (leptin, adiponectin, resistin) have been evaluated in both groups. Methods. 75 patients with PA (37 Males, 38 Females; age 52.9±11.4 years, range 20-76 years), 40 healthy patients (HS) (24 M, 16 F, age 55.7 ± 6.1 years), 152 patients with EH without MS (80 M, 72 F, age 55.6 ± 12.4 years), 40 patients with EH and MS (22 M, 18 F, age 56.8±10.9 years). Results. In 25.3% patients with PA was present MS, patients with PA and MS showed reduced levels of adiponectin (8.9±0.8 μg/ml) compared to patients with PA without MS (12±0.9 μg/ml; p
Data Loading...
